Nieuws en video's - GlobeNewsWire

Heineken ® says cheers to the Real Hardcore Fans as thousands of fans faces adorn the celebration confetti during the UEFA Champions League Final 2024 Trophy Lift at Wembley LONDON, June 01, 2024 (GLOBE NEWSWIRE) -- Tonight, Heineken ® has created a way for thousands of ‘real hardcore fans’ to take part in the UEFA Champions League Final Trophy celebration, marking the culmination of the ‘ Cheers To The Real Hardcore Fans ’ 2024 campaign. Following the final whistle, Heineken ®...

In 17 EGFR wild-type ( EGFR wt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months Objective responses were also seen in 4 of 13 response-evaluable EGFR mutant ( EGFR mut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patients In both NSCLC cohorts, the...

CALGARY, Alberta, June 01, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. (" Prospera " or the " Corporation ") (PEI: TSX-V; OF6A: FRA) 2023 was a transformational year for Prospera transforming to horizontal well technology in the Saskatchewan heavy-oil fields. Also, to initiate medium/light-oil development to diversify from predominately a heavy oil producer. The company successfully drilled, completed, and tied in 9 horizontal wells in its Saskatchewan heavy-oil fields and 1 slanted well in...

Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeks Data from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 Genmab A/S (Nasdaq:...

Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeks Data from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab...

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7) Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolved Early PK data...

- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expansion selected and expansion arms open for enrollment - - Preliminary data on WTX-124 administered to patients in combination with pembrolizumab showed that the combination was...

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in...

NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM ( NCT04382664 ), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website:...

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafusp (IMC-F106C) in advanced cutaneous melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, June 1, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”)...

Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favorable and manageable safety profile observed at all tested dose levels Weekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamics Data support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR...

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors KT-253 Phase 1 study ongoing with additional data expected in the...

CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1 clinical trial. As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer...

NE PAS DISTRIBUER AUX AGENCES DE PRESSE DES ÉTATS-UNIS ET NE PAS DIFFUSER AUX ÉTATS-UNIS LONDON, Province de l’Ontario, 01 juin 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. . (« Aduro » ou la « société ») (CSE : ACT ) (OTCQX : ACTHF ) (FSE : 9D50 ), une société technologique canadienne utilisant le pouvoir de la chimie pour transformer des matières premières de moindre valeur, telles que les déchets plastiques, le bitume lourd et les huiles renouvelables, en ressources...

NIO delivered 20,544 vehicles in May 2024, increasing by 233.8% year-over-year NIO delivered 66,217 vehicles year-to-date in 2024, increasing by 51.0% year-over-year Cumulative deliveries of NIO vehicles reached 515,811 as of May 31, 2024 SHANGHAI, June 01, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its May 2024 delivery results. NIO delivered...

GUANGZHOU, China, June 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for May 2024. XPENG delivered 10,146 Smart EVs in May, representing a 35% increase year-over-year and an 8% increase over the prior month. The XPENG X9 notably achieved monthly deliveries of 1,625 units, reaching a cumulative total of 11,456 units, and has...

Luxembourg – 1 June 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced, after a competitive tender process, the award by Petrobras of four long-term day-rate contracts for pipelay support vessels (PLSVs) commencing in 2025. The contracts have a combined value of over $1.25 billion and will be recorded in the backlog in the second quarter. The contracts for Seven Rio , Seven Cruzeiro and Seven Sun comprise a firm three-year period while the award for Seven Waves comprises a...

Press release/Investor news Copenhagen, 1st of June 2024 Swiss Properties Invest AG has acquired a commercial property in Koblenz in the canton of Aargau. The property has 5’023 m 2 usable space and the land size is 7’673 m 2 . The acquired property represents a very attractive opportunity to Swiss Properties Invest delivering on all four acquisition criteria stated in the IPO prospectus from 2022. Management sees a further opportunity to increase the yield with the addition of solar panels....